@article{43c47ad9e3814e4285c09e208c46bb6e,
title = "Non-right handed primary progressive apraxia of speech",
abstract = "In recent years a large and growing body of research has greatly advanced our understanding of primary progressive apraxia of speech. Handedness has emerged as one potential marker of selective vulnerability in degenerative diseases. This study evaluated the clinical and imaging findings in non-right handed compared to right handed participants in a prospective cohort diagnosed with primary progressive apraxia of speech. A total of 30 participants were included. Compared to the expected rate in the population, there was a higher prevalence of non-right handedness among those with primary progressive apraxia of speech (6/30, 20%). Small group numbers meant that these results did not reach statistical significance, although the effect sizes were moderate-to-large. There were no clinical differences between right handed and non-right handed participants. Bilateral hypometabolism was seen in primary progressive apraxia of speech compared to controls, with non-right handed participants showing more right hemispheric involvement. This is the first report of a higher rate of non-right handedness in participants with isolated apraxia of speech, which may point to an increased vulnerability for developing this disorder among non-right handed participants. This challenges prior hypotheses about a relative protective effect of non-right handedness for tau-related neurodegeneration. We discuss potential avenues for future research to investigate the relationship between handedness and motor disorders more generally.",
keywords = "FDG-PET imaging, Handedness, Primary progressive aphasia, Progressive apraxia of speech",
author = "Hugo Botha and Duffy, {Joseph R.} and Whitwell, {Jennifer L.} and Strand, {Edythe A.} and Machulda, {Mary M.} and Spychalla, {Anthony J.} and Nirubol Tosakulwong and Senjem, {Matthew L.} and Knopman, {David S.} and Petersen, {Ronald C.} and Jack, {Clifford R.} and Lowe, {Val J.} and Josephs, {Keith A.}",
note = "Funding Information: Dr. Botha reports no disclosures. Dr. Duffy reports no disclosures. Dr. Whitwell receives funding from the NIH and NIDCD. Dr. Strand reports no disclosures. Dr. Machulda reports no disclosures. Anthony Spychalla reports no disclosures. Nirubol Tosakulwong reports no disclosures. Matthew L. Senjem reports no disclosures. Dr. Knopman receives research support from the NIH and the Robert H. and Clarice Smith and Abigail Van Buren Alzheimer's Disease Research Program of the Mayo Foundation. He serves on a Data Safety Monitoring Board for Lundbeck Pharmaceuticals and for the DIAN study, and is an investigator in clinical trials sponsored by Biogen, TauRX Pharmaceuticals, Lilly Pharmaceuticals and the Alzheimer's Disease Treatment and Research Institute, University of Southern California. Dr. Petersen serves as a consultant for Merck Inc., Roche Inc., Biogen Inc., and Genentech Inc.; receives publishing royalties for Mild Cognitive Impairment (Oxford University Press, 2003); and receives research support from the NIH, the GHR Foundation and the Mayo Foundation for Medical Education and Research. Dr. Jack receives research funding from the NIH and the Alexander Family Alzheimer's Disease Research Professorship at Mayo Clinic. Dr. Lowe is a consultant for Bayer Schering Pharma, Merck Research, Piramal Imaging Inc., and receives research support from GE Healthcare, Siemens Molecular Imaging, AVID Radiopharmaceuticals, the NIH (NIA, NCI), the Elsie and Marvin Dekelboum Family Foundation, the Liston Family Foundation, and the MN Partnership for Biotechnology and Medical Genomics. Dr. Josephs receives funding from the NIH and NIDCD. Funding Information: This research was supported by NIH grants R01-DC010367 (PI Josephs), R01-DC12519 (PI Whitwell), R21NS094684 (PI Josephs), U01 AG006786 (PI Petersen), R01 AG11378 (PI Jack), R01 AG041851 (PIs Knopman, Jack) as well as funding from The Elsie and Marvin Dekelboum Family Foundation (Lowe). In addition, we appreciate support from the Robert H. and Clarice Smith and Abigail van Buren Alzheimer's Disease Research Program; the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic ; and the Mayo Foundation for Medical Education and Research . Publisher Copyright: {\textcopyright} 2018",
year = "2018",
month = jul,
day = "15",
doi = "10.1016/j.jns.2018.05.007",
language = "English (US)",
volume = "390",
pages = "246--254",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
}